Gilead Sciences

This early-stage study tested the safety of two experimental therapeutic vaccines (GS-2829 and GS-6779) designed to treat chronic hepatitis B. The study involved 83 participants, including both healthy volunteers and people with stable, well-controlled hepatitis B infection. The …

This study aimed to learn more about the long-term safety of the cancer drug sacituzumab govitecan. It was for a small group of people (25 participants) whose metastatic cancer had already been controlled by this drug in a previous study. The main goal was to monitor for any side…

This study tested whether two different drug combinations could improve liver scarring and reduce inflammation in people with advanced liver disease caused by NASH, a serious form of fatty liver disease. It involved 457 participants with compensated cirrhosis. The goal was to see…

This study looked at how safe it is for people with well-controlled HIV to switch from getting treatment through injections every two months to taking a daily pill instead. It involved 33 participants who wanted to change from the injection regimen, often due to side effects or i…

This study tested a single-tablet HIV medication in children and teens. It aimed to find the right dose, check how the body processes the drug, and see if it was safe and effective at controlling the virus. The study included 129 young people, from ages 2 to 18, who were either n…

This study tested the safety of a new combination treatment for HIV. It involved 20 women who were already on successful HIV medication. Researchers gave them two long-acting antibodies and an immune system booster, then carefully paused their regular pills to see if the new trea…

This early-stage study tested how the hepatitis D drug bulevirtide behaves in people with different levels of kidney function. Researchers gave the drug to 41 people, some with healthy kidneys and some with impaired kidney function. They measured how much drug got into the blood,…

This early-stage study aimed to understand how liver function affects the way the body processes bulevirtide, a medication for hepatitis D. Researchers compared 74 participants—some with healthy livers and some with impaired liver function—to measure drug levels in the blood and …